MLYS - Mineralys Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$46.00
DETAILS
HIGH:
$56.00
LOW:
$30.00
MEDIAN:
$52.00
CONSENSUS:
$46.00
UPSIDE:
54.10%
About Mineralys Therapeutics, Inc. (https://mineralystx.com)
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Jon Congleton | President, Chief Executive Officer & Director | 1963 | $1,109,101 USD |
| David Rodman | Chief Medical Officer | 1955 | $881,798 USD |
| Adam Scott Levy | Chief Financial Officer & Secretary | 1978 | $880,190 USD |
| Brian Taylor Slingsby | Founder & Executive Director | 1977 | $78,000 USD |
| Danielle Mahoney | Senior Vice President of Quality Assurance | – | – |
| Eric J. Warren | Chief Commercial Officer | 1972 | – |
| Jeffrey A. Munsie | Chief Legal Officer | 1977 | – |
| Jessica Ibbitson | Executive Vice President of Operations | – | – |
| Michael Tortorici | Senior Vice President of Translational Medicine | – | – |
| Robert McKean | Senior Vice President of CMC | – | – |
| Sarah Foster | Senior Vice President of People | – | – |
| Tiffany Ellen Burt | Senior Vice President of Medical Affairs | – | – |